FTOrs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients

Table 2 Relationship between rs9939609 polymorphism

Outcomes	All patients	TT	AT	AA	P-value^(a)	aAMR (95%CI)	P-value^(b)
Continuous variables
BMI (kg/m²)	23.29 ± 0.25	22.69 ± 0.35	22.91 ± 0.32	24.29 ± 0.58	0.016	1.08 (1.03; 1.14)	0.002
HOMA-IR	3.24 ± 0.19	2.97 ± 0.29	2.75 ± 0.26	4.19 ± 0.47	0.003	1.32 (1.03; 1.69)	0.027
	All patients	TT	AT	AA	P -value ^(a)	aOR (95%CI)	P -value ^(b)
Categorical variables
Overweight (BMI ≥27.5 kg/m²)	8.5% (22/260)	4% (4/100)	8.9% (11/123)	19.4% (7/36)	0.011	3.46 (1.17; 10.21)	0.024
HOMA-IR ≥2.5	41.4% (108/261)	38.6% (39/101)	39% (48/123)	56.8% (21/37)	0.040	2.09 (1.02; 4.32)	0.045
Significant fibrosis (F ≥ 2)	48.6% (102/210)	48.8% (41/84)	43.3% (42/97)	65.5% (19/29)	0.049	2.34 (1.02; 5.36)	0.045
Steatosis (>10% fatty hepatocytes)	56.9% (115/202)	51.9% (41/79)	57% (53/93)	70% (21/30)	0.117	3.65 (1.29;10.36)	0.015

^a P-values were calculated by Chi-square tests for categorical variables and generalized linear models (GLM) with normal distribution (log-link) for continuous variables; ^b P-values were calculated by GLM adjusted by the most important clinical and epidemiological characteristics (see Statistical analysis section). Metabolic disturbances and liver disease in HIV/HCV-coinfected patients. Categorical variables are expressed in percentage (absolute count) and continuous variables are expressed in estimated marginal mean ± standard error of the mean. Statistically significant differences are shown in bold. 95%CI, 95% confidence interval; aAMR, adjusted arithmetic mean ratio; aOR, adjusted odds ratio; BMI, body mass index; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HOMA-IR, homeostatic model assessment-insulin resistance.

ISSN: 1741-7015